Bedrijfsoverzicht
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to the discovery and development of small molecule inhibitors designed to assist patients suffering from cancer. The company operates within the healthcare sector, specifically inside the biotechnology industry, which typically involves high research and development expenditures before products reach commercialization. The enterprise maintains a substantial market capitalization of $2.71 billion while employing a workforce of 60 individuals. Despite the significant market cap figure relative to its operational scale and the absence of reported annual revenue data, these metrics indicate that the company holds a valuation that reflects investor confidence in its potential future clinical outcomes rather than current cash flow generation. The disparity between the large market valuation and the lack of revenue highlights the pre-revenue nature of clinical-stage biotechnology firms where value is derived from intellectual property and pipeline progress rather than sales figures.
Financiële gezondheid
The financial statements for Enliven Therapeutics, Inc. report a Net Income (TTM) of $-103,694,000 and an EBITDA of $-119,395,000, with Revenue (TTM) listed as N/A due to the pre-commercial status of its clinical programs. The substantial gap between the reported net income and the EBITDA figure reveals a cost structure heavily influenced by non-operating expenses and interest costs, as the operating loss is slightly less severe than the net loss. The company generates a Free Cash Flow of $-47,978,248, indicating a continuous burn rate that necessitates significant external capital raising to maintain its clinical trials and operational activities. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which signifies that the company has not yet generated commercial sales to establish a profitable revenue base. On the balance sheet, the firm holds $462.62 million in cash against a total debt obligation of $399,000, supported by a Debt to Equity ratio of 0.09 and a Current Ratio of 28.66. This liquidity position demonstrates an extremely conservative balance sheet with minimal leverage and ample short-term assets relative to liabilities. The Return on Equity stands at -27.0% and the Return on Assets is -18.7%, metrics that reflect the dilutive impact of operating losses on shareholder value and the company's asset base efficiency during the development phase.
Waarderingsbeoordeling
Valuation multiples for Enliven Therapeutics, Inc. include a P/E Ratio (TTM) of N/A and a Forward P/E of -17.84, the negative forward multiple implying that the market expects earnings to remain negative or for the current losses to persist in the near term. The Price to Book ratio is calculated at 5.86, suggesting that the market values the company's equity at a significant premium compared to its net book value, a common phenomenon in biotechnology where intangible assets are undervalued on the balance sheet. Alternative valuation metrics such as the Price to Sales ratio, which is N/A, and the EV/EBITDA of -18.83, further illustrate that traditional valuation models are less applicable to this pre-revenue stage company. The stock's price action over the last year has ranged between a 52-Week High of $46.31 and a 52-Week Low of $14.79, with the current trading price situated somewhere within this wide volatility band. The Beta of 0.49 indicates that the stock's price volatility is significantly lower than the broader market, suggesting less sensitivity to general market fluctuations despite the high-risk nature of its clinical pipeline.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, reflecting the fact that the company has not yet established a recurring revenue stream to calculate year-over-year expansion rates. Consequently, there is no dividend yield or payout ratio to analyze, as the company maintains a Dividend Yield of N/A and a Payout Ratio of 0.0%. Instead of distributing profits to shareholders, the company reinvests all available financial resources, including its $462.62 million cash reserve, directly into research, development, and clinical trials to advance its cancer inhibitor programs. The overall growth and income profile of Enliven Therapeutics, Inc. is currently defined by a focus on capital preservation and pipeline advancement rather than financial returns or dividend distributions to investors.